Prioritized analogs based on potency, selectivity, solubility and predicted BBB permeability were further evaluated at additional AC isoforms. The molecules were observed to potentiate AC2 activity but did not display any modulatory effect against AC5. Additionally, the prioritized analogs were largely inactive at all opioid receptors and against selected kinases. Finally, when evaluated in a murine CFA model for inflammatory pain analog 38 displayed modest antiallodynic properties with a significant effect at the 1-hour post-treatment time point, demonstrating the potential of the scaffold for relieving pain. Further studies will focus on improvement of physicochemical and pharmacokinetic properties while maintaining AC1 potency and selectivity to enhance in vivo efficacy.